This year, U.S. VC funding into the life sciences sector has cooled: Q1 softness was followed by a decade low in VC transactions in Q2. Despite the moderation in dealmaking volume, investors continued to deploy sizable...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2023 include:
• Life sciences VC deal value totaled $5.0 billion across 364 deals, representing a 40.9% decline in value...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include:
• Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more